ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Otsuka Holdings Co., Ltd.

Business Summary

Otsuka Holdings Co., Ltd. engages in the manufacture and sale of pharmaceuticals and nutritional supplements. It operates through the following business segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segment manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals segment develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products segment sells mineral water, food, and beverages. Its products include Bon Curry, Mannan Hikari, and ReSOLA. The Others segment distributes functional and fine chemicals, optical inspection devices, and clinical diagnosis equipment. The company was founded in1950 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2020 JPYUSD
Revenue1,422.82B13,326.26M
Gross Profit983,110M9,207.86M
Operating income203,835M1,909.13M
Income before tax189,988M1,779.43M
Net income148,137M1,387.45M
EBITDA283,258M2,653.01M
Diluted EPS272.352.55
Dividends Per Share1000.93
Total Assets2,627.80B25,452.14M
Total liabilities744,371M7,209.75M
Total equity1,852.37B17,941.54M
Operating cash flow232,839M2,180.78M
Currency in JPYCurrency in USD

Historical Data

 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 1,195.74B 1,239.95B 1,291.98B 1,396.24B 1,422.82B
Gross Profit 789,415M 817,540M 850,149M 944,943M 983,110M
Operating income 84,435M 112,679M 104,377M 171,547M 203,835M
Income before tax 100,706M 103,712M 109,497M 173,515M 189,988M
Net income 92,563M 112,492M 82,492M 127,152M 148,137M
EBITDA 144,009M 174,914M 163,652M 247,237M 283,258M
Diluted EPS 170.70 206.99 151.26 231.13 272.35
Dividends Per Share 100 100 100 100 100
Total Assets 2,478.29B 2,480.25B 2,477.36B 2,581.30B 2,627.80B
Total liabilities 739,845M 658,303M 745,094M 785,863M 744,371M
Total equity 1,710.53B 1,793.27B 1,704.49B 1,766.27B 1,852.37B
Operating cash flow 142,004M 102,832M 135,821M 192,634M 232,839M
 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 11,004.58M 11,057.80M 11,698.18M 12,808.27M 13,326.26M
Gross Profit 7,265.07M 7,290.76M 7,697.63M 8,668.34M 9,207.86M
Operating income 777.06M 1,004.86M 945.07M 1,573.66M 1,909.13M
Income before tax 926.80M 924.89M 991.43M 1,591.72M 1,779.43M
Net income 851.86M 1,003.19M 746.92M 1,166.41M 1,387.45M
EBITDA 1,325.33M 1,559.87M 1,481.78M 2,268.00M 2,653.01M
Diluted EPS 1.57 1.84 1.36 2.12 2.55
Dividends Per Share 0.92 0.89 0.90 0.91 0.93
Total Assets 21,248.25M 22,017.36M 22,579.98M 23,752.55M 25,452.14M
Total liabilities 6,343.25M 5,843.79M 6,791.17M 7,231.31M 7,209.75M
Total equity 14,665.67M 15,919.02M 15,535.69M 16,252.79M 17,941.54M
Operating cash flow 1,306.87M 917.04M 1,229.78M 1,767.10M 2,180.78M

Valuation Measures

Dec 2020
PER16.17
ROA5.68%
ROE8.18%
Operating margin14.32%
Profit margin10.41%

Key executives

  • President, CEO & Representative Director: Tatsuo Higuchi
  • Chief Financial Officer & Director: Yuko Makino
  • Vice President-Global Clinical Development: Frank Czerwiec
  • Head-Business Development: Yasuhisa Kurogi
  • Director & Head-Business Portfolio Management: Shuichi Takagi

Shareholders

  • OTSUKA FAMILY /OTSUKA HOLDINGS/ (15.8%)
  • Nomura Asset Management Co., Ltd. (4.3%)
  • Otsuka Holdings Co., Ltd. (2.7%)
  • Otsuka Holdings Employee Stock Ownership Plan (2.3%)
  • Daiwa Asset Management Co. Ltd. (2.0%)
  • Nikko Asset Management Co., Ltd. (2.0%)
  • The Awa Bank Ltd. (1.9%)
  • The Vanguard Group, Inc. (1.8%)
  • T. Rowe Price International Ltd. (1.5%)
  • BlackRock Fund Advisors (1.1%)

Contact Details

  • Website:http://www.otsuka.com
  • Address: Shinagawa Grand Central Tower, 12/F, 2-16-4 Konan, Tokyo, 108-8241, Japan
  • Phone: +81.3.6717.1410

Related Companies

  • Otsuka Europe Development & Commercialisation Ltd.
  • Otsuka Holdings Restricted Stock Compensation Plan
  • Otsuka Shanghai Research Institute
  • Otsuka Pharmaceutical (Switzerland) GmbH
  • Otsuka Pharmaceutical (HK) Ltd.
  • Otsuka America Foods, Inc.
  • Otsuka Pharma Scandinavia AB
  • Sichuan Otsuka Pharmaceutical Co. Ltd.
  • Otsuka (Shanghai) Foods-Safety Research & Development Co. Ltd.
  • Shanghai Otsuka Foods Co. Ltd.
  • Otsuka Pharmaceuticals (U.K.) Ltd.
  • Taiho Oncology, Inc.
  • Tianjin Otsuka Beverage Co., Ltd.
  • ReCor Medical, Inc.
  • Otsuka Medical Devices Co., Ltd.
  • Otsuka Holdingse Mployee Incentive Plan
  • Otsuka Holdings Employee Stock Ownership Plan
  • Otsuka Techno Corp.
  • Otsuka Foods Co., Ltd.
  • JIMRO Co., Ltd.
  • Nutrition & Sante' Italia SpA
  • Otsuka Pharma GmbH
  • Otsuka Packaging Ind Co. Ltd.
  • Nutrition & Sante SAS
  • Otsuka Pharmaceutical SA
  • Nardobel SAS
  • Nutrition et Soja
  • Nutrition & Sante Iberia SL
  • JO Pharma KK
  • Otsuka Electronics Co., Ltd.

Competitors

  • GlaxoSmithKline plc
  • JW Holdings Corporation
  • Tonix Pharmaceuticals Holding Corp.
  • Church & Dwight Co., Inc.
  • Supernus Pharmaceuticals, Inc.
  • Cerevel Therapeutics Holdings Inc
  • VistaGen Therapeutics, Inc.
  • Qurient Co., Ltd.
  • FibroGen, Inc.
  • Aytu BioPharma, Inc.
  • Vivoryon Therapeutics N.V.
  • Rafael Holdings, Inc. Class B
  • Addex Therapeutics Ltd
  • Aptinyx Inc
  • Axsome Therapeutics, Inc.
  • Reata Pharmaceuticals, Inc. Class A
  • Kinnate Biopharma, Inc.
  • Vanda Pharmaceuticals Inc.
  • Deciphera Pharmaceuticals, Inc.
  • Selecta Biosciences, Inc.
  • CrystalGenomics Inc.
  • Intra-Cellular Therapies, Inc.
  • Minerva Neurosciences Inc
  • ACADIA Pharmaceuticals Inc.
  • Adamas Pharmaceuticals, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • BioLineRX Ltd.
  • SELLAS Life Sciences Group, Inc.
  • Aprea Therapeutics, Inc.
  • Alkermes Plc
Last Updated on 21 Oct, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more